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Results: For dataset A, n = 9213 and B, n = 1244. The most fre-
quently dispensed antidepressant was amitriptyline (A: 67.75%, 
n = 6242; B: 64.06%, n = 797). The mean age of patients was 43.86 
(13.81) and 46.27 (13.07), respectively. The type of antidepressant 
used was significantly associated with ICD-10 code, psychiatric 
condition, and categorical age (P < 0.0001). The mean number of 
antidepressant prescriptions per patient were: A, 2.95 (3.77); and B, 
2.57 (2.47). Duration of treatment was related to age, ICD-10 code, 
and psychiatric condition (P < 0.0001).
Conclusion: Since their inception, there has been a steady increase 
in global antidepressant prescriptions, despite controversies concern-
ing efficacy and safety of these drugs. This trend is also evident in 
South Africa: This research shows that amitriptyline accounts for a 
majority of prescriptions because of its varied indications for use. 
The determinants of the type of antidepressant used showed that 
patients with a psychiatric condition were more likely to receive a 
newer antidepressant, and patients with a pain condition were more 
likely to receive an older antidepressant. These results will ultimately 
be compared with DUR data from the private and general public 
sectors of Gauteng health services to establish a baseline for making 
recommendations concerning safety, efficacy, and cost-effectiveness 
of antidepressant use in Gauteng.
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Introduction: Pregabalin, an agent in treating partial epilepsy and 
peripheral neuropathic and central pain, was studied for its effect on 
driving performance in healthy volunteers. The study was approved 
by the ethical committee of Ehime University Hospital. Written 
informed consent was obtained from the volunteers before partici-
pation in the study, which was performed in accordance with the 
principles of the Declaration of Helsinki.
Patients (or Materials) and Methods: Sixteen regularly driving, 
healthy male volunteers were enrolled for a double-blind placebo 
control study of pregablin on driving performance. Driving simulator 
was used to test the simple and complicated braking reaction time, 
simple and complicated steering wheel techniques. Pregabalin was 
also evaluated for the effect of training on driving tests.
Results: The mean (SD) age of pregabalin and placebo groups were 
26.0 (2.9) and 28.6 (3.5) years, respectively. The body weight, plasma 
creatinine level, and eGFR of pregabalin group were 69.0 (4.7) kg, 
0.8 (0.04) mg/dL, and 94.1 (5.7) mL/min, respectively. The body 
weight, plasma creatinine level, and eGFR of placebo group were 
62.16 (4.6) kg, 0.8 (0.05) mg/dL, and 96.7 (6.5) mL/min, respectively. 
Six members of the pregabalin group and 2 members of placebo 
group reported sleepiness. The other 2 members of the pregabalin 
group presented somnolence during driving. All the subjects showed 
no serious adverse effects. There were no significant differences of 
both simple and complicated braking reaction time between pregaba-
lin and placebo groups. The simple and complicated wheel techniques 
also showed no differences between pregabalin and placebo groups. 
In comparing the effect of training on the driving performance, the 
placebo group showed the improvement in the test of simple steering 
wheel technique. The number of errors in handling wheel detected 1 
hour and 2 hours from the baseline showed significantly reduction 
compared with the baseline data. However, the pregabalin group 
showed no improvement in handling wheels with the training. Both 
pregabalin and placebo groups had no changes in both simple and 
complicated braking reaction time, and complicated handling wheel 
tests.
Conclusion: In our study using driving simulator, pregablin exhibited 
no serious central nervous system side effects in engaging driving, but 
caused mild effects to decrease the training of driving.
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Introduction: To calculate the incidence, describe the suspected cases 
of paracetamol poisoning, and determine the differences between the 
patterns of acute versus chronic ingestion in patients < 18 years of 
age who were treated at a tertiary hospital.
Patients (or Materials) and Methods: Retrospective cohort study 
of patients < 18 years of age who were treated in the emergency 
department (pediatric and general) of the La Paz University Hospital 
for suspected paracetamol intoxication and for whom paracetamol 
serum level tests were requested.
Results: Ninety-two (92) patients with suspected paracetamol 
poisoning were identified between 2005 and 2010. The incidence 
for 2007 was 1.53 cases (95% CI Poisson, 0.24–5.57) per 10,000 
patients treated at the pediatric emergency department. The most 
common cause of poisoning was attempted suicide (47.8%), with a 
median age of 15 years, followed by accidental poisoning (42.2%), 
with a median age of 2.65 years. Following the assessment of causal-
ity, we found that 1 patient with acute poisoning showed a hepatic 
disorder secondary to paracetamol, while 7 of the 11 patients with 
chronic poisoning showed liver enzyme disorders secondary to par-
acetamol poisoning. The time required to find medical care was 6.83 
hours for acute poisoning and 52.3 hours for chronic poisoning 
(P < 0.001).
Conclusion: Chronic paracetamol poisoning is a potential risk factor 
for hepatotoxicity and ALF; delays in seeking medical help may be a 
contributing factor. The parents/guardians should therefore be noti-
fied of this fact, and the ED physicians’ clinical suspicion increased.
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Introduction: Misuses of buprenorphine concern ~30% of patients 
treated for drug detoxification in cases of opioid abuse. Injecting pills 
that are not intended for intravenous (IV) administration may have 
harmful consequences, particularly because of particles. The main 
difference between Subutex® and its generics concern the insoluble 
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particles subsets. The aim of our work was to determine, by analyz-
ing injected solutions, if the misuses of the generics could be more 
dangerous than that of the Subutex®.
Patients (or Materials) and Methods: Injection material used 
was contained in Steribox®II Kit. Solutions were prepared using 
Subutex® 8 mg or buprenorphine 8 mg generic as follows: tablet 
was dissolved in 1 mL of water, mashed with the syringe’s piston, 
and filtered through a cotton pad or a Sterifilt®. Quantification of 
buprenorphine concentration was performed by U-HPLC; particles 
size distribution was performed by laser granulometry and flow 
cytometer.
Results: Seventy percent to 100% of the dose of buprenorphine 
contained in a tablet was found in the solution, whatever the drug 
and the filter used. After filtration with cotton pad, the maximal size 
of the particles found in solution reached 100 µm for the generic 
and 47 µm for Subutex®. With Sterifilt®, the maximal size of the 
particles were 36 µm for the generic and under the limits of the laser 
granulometer for Subutex®. These results were confirmed by flow 
cytometer: after Sterifilt® filtration, more particles > 5 µm were found 
for the generic with regard to the princeps.
Conclusion: Extraction recovery of buprenorphine tablets was excel-
lent and similar for both princeps and generic. These results confirm 
that buprenorphine remains an excellent candidate for misuse. We 
have highlighted the wide variation of the quantity and the size of 
the particles present in solution between the 2 drugs after cotton pad 
filtration. According to these preliminary results, misuse of injected 
buprenorphine could be more dangerous with the generic form than 
with the princeps, in particular in term of thromboembolic events.
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Introduction: Soy products are used in human diet and in food 
additives because of their beneficial effects in menopause and their 
potential protective effects in cancer and other diseases. Nevertheless, 
genistein and other phytoestrogens contained in soy may disrupt the 
endocrine system by modulating the hypothalamic-pituitary-gonadal 
axis, and thus they may influence spermatogenesis and reproduction. 
The objective of this study was to investigate the adverse effects of 
chronic soy diet on the histologic characteristics of the reproductive 
organs in adult male rats.
Patients (or Materials) and Methods: Two groups of adult male 
albino Wistar rats, 6 months old, were used: the study group and the 
control group. The study group received ad libidum food enriched 
in soy protein for 3 months. The control group received ad libidum 
the standard food for 3 months. Both groups were grown under the 
same conditions and according to the rules of Good Laboratory 
Practice. The study was approved by the local ethics committee. 
The animals of both groups were sacrificed, and specimens of the 
reproductive organs were prepared and stained for microscopic 
examination. The preparations were observed by 2 different per-
sons, blinded to the source of the specimen. Statistical analysis was 
performed with the statistical package SPSS.
Results: The seminiferous epithelium of the testes was found lower 
and contained fewer layers of spermatocytes in the study group com-
pared with the control group. Similar changes were observed in the 
epididymidal epithelium and the epithelium of the vas deferens and 
the seminal vesicles of the study group. The number of spermatozoa 
in the seminiferous tubules of the testes, in epididymis, and in the vas 
deferens was much lower in rats fed with soy diet compared with the 
rats fed with standard food.
Conclusion: Chronic soy diet causes histologic changes in the repro-
ductive organs and influences the number of spermatozoa in the testes 
of the adult rats. Diet containing phytoestrogens may influence male 
fertility and should probably be avoided in a chronic basis when 
pregnancy is desired.
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Introduction: Enforcement of new EU Pharmacovigilance (PV) 
Regulation 1235/2010 and Directive 2010/84/EU, in July 2012, 
caused differencies from local PV regulations of some European 
non-EU countries. Consequently, disturbances of PV practices have 
been caused at local affiliates of international pharma companies 
who based their operational procedures on local law aligned with 
EU Legislation.
Patients (or Materials) and Methods: The review and comparison 
of EU PV Legislation and Local PV Regulation of Serbia 64/2011 
were done. Main differences are listed and their impact on local 
PV practice is presented. Local PV regulation of Serbia was chosen 
becaue: (1) authors are from Serbia; and (2) the local regulation is 
more complex than others in the region.
Challenges in local PV practices are presented based on experience 
of Janssen local safety unit (LSU).
Results: Main differences: (1) Pharmacovigilance System Master 
File (PSMF) and Summary of Pharmacovigilance System (SPS) vs. 
Detailed Description of Pharmacovigilance System (DDPS);
(2)Periodicity and timelines for Periodic Safety Update Reports 
(PSUR) submission;
(3)European Risk Management Plan (EU RMP) vs. RMP
(4)Safety reports for renewals: Addendum Clinical Overview 
(ACO) vs. Summary Bridge Report (SBR) and Addendum report (AR).
(1)According to EU legislation, SPS has to be submitted to 
European Medicines Agency and PSMF only in case of explicit 
requirement. According to local requirements, global and local DDPS 
are needed. SPS is not enough. PSMF accepted, but could not be 
requested. Appropriate global document is milestone to be compliant 
and to obtain approval/renewal license.
(2)Locally, periodicity, and timeline for PSUR submission are still 
“old.” However, Local Health Authority (LHA) accepts European 
Union Referens Dates (EURD) list for “centralized products” (CP) 
and for non-CP with renewals. Unevenness requires enhanced moni-
toring of PSUR periodicity and timelines and make compliance dif-
ficult.
(3)Locally, EU RMP is accepted. However, implementation is 
delayed since LHA based approval on EMA approval.
(4)Locally, SBR and AR are required for renewals. LHA tends 
to accept ACO, but currently, only as additional document. 
Consequences are additional effort and cost for Company to prepare 
SBR and AR, and ACO, in addition.
Overall, LHA has not had access to EudraVigilance database, 
and worldwide individual case safety reports have to be submitted 
to LHA by LSU, which is time-consuming.
